ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
Rhea-AI Summary
ALX Oncology (Nasdaq: ALXO) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City. CEO Jason Lettmann will engage in a fireside chat with analyst Christopher Raymond on December 3, 2024, at 9:30 AM EST. The event will also include one-on-one meetings.
The fireside chat will be accessible via webcast through ALX Oncology's website investor section, with a replay available for up to 90 days following the event. ALX Oncology is a clinical-stage biotechnology company focused on developing immune system-boosting cancer therapies to extend patient lives.
Positive
- None.
Negative
- None.
News Market Reaction – ALXO
In the trading session that priced this news, ALXO gained 1.36%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that Jason Lettmann, the Company’s Chief Executive Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held in New York City from December 3-5, 2024.
Format: Fireside chat with analyst, Christopher Raymond and 1x1 meetings
Date: Tuesday, December 3, 2024
Time: 9:30 AM EST
Location: New York City, NY
Webcast link: Available here
The live webcast for the Piper Sandler fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
